VOR
Vor Biopharma Inc.
Price Chart
Latest Quote
$17.34
-0.74 (-4.09%)
Current Price
| Previous Close | $18.08 |
| Open | $17.90 |
| Day High | $18.37 |
| Day Low | $17.14 |
| Volume | 833,740 |
Stock Information
| Shares Outstanding | 54.19M |
| Total Debt | $2.94M |
| Cash Equivalents | $491.52M |
| Net Income | $-883.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $980.22M |
| EPS (TTM) | $-73.40 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $491.64M |
| Income | $-883.08M |
| Book/sh | $-2.78 |
| Cash/sh | $9.07 |
| Employees | 76 |
Financial Ratios
| Quick Ratio | 30.57 |
| Current Ratio | 31.15 |
Returns & Margins
| ROA | -69.76% |
Ownership
| Insider Ownership | 4.27% |
| Institutional Ownership | 69.56% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.83 |
| P/B | -6.52 |
Analyst Data
| Recommendation | none |
| Target Price | $37.88 |
Technical Indicators
| SMA20 | $17.76 |
| SMA50 | $15.93 |
| SMA200 | $16.34 |
| RSI | 59.69 |
| ATR | 1.6996 |
| Shares Float | 40.17M |
| Short Float | 17.09% |
| Short Ratio | 5.41 |
| Volatility | 1.70 |
| Rel Volume | 0.53 |
Performance History
| Week | -5.49% |
| Month | +28.21% |
| Quarter | +20.84% |
| 6 Months | +22.48% |
| YTD | +55.41% |
| Year | -57.33% |
| 3 Years | -69.55% |
| 5 Years | -95.28% |
| 10 Years | -97.59% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $18.09 | 999,000 |
| 2026-07-16 | $17.34 | 849,600 |
| 2026-07-15 | $18.08 | 767,600 |
| 2026-07-14 | $18.50 | 911,900 |
| 2026-07-13 | $18.03 | 1,107,800 |
| 2026-07-10 | $19.14 | 2,184,700 |
| 2026-07-09 | $19.75 | 1,597,600 |
| 2026-07-08 | $20.31 | 2,135,500 |
| 2026-07-07 | $20.10 | 1,369,100 |
| 2026-07-06 | $20.10 | 1,594,800 |
| 2026-07-02 | $20.59 | 3,910,600 |
| 2026-07-01 | $18.39 | 1,388,800 |
| 2026-06-30 | $18.41 | 1,378,500 |
| 2026-06-29 | $18.60 | 2,818,600 |
| 2026-06-26 | $16.10 | 8,125,900 |
| 2026-06-25 | $14.93 | 903,600 |
| 2026-06-24 | $14.48 | 742,300 |
| 2026-06-23 | $14.85 | 1,260,900 |
| 2026-06-22 | $14.94 | 800,100 |
| 2026-06-18 | $14.49 | 2,875,000 |
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as SjÃļgren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
đ° Latest News
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
Simply Wall St. âĸ 2026-06-30T15:08:26Z
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
Motley Fool âĸ 2026-05-30T18:12:32Z
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Motley Fool âĸ 2026-05-30T16:48:24Z
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
Simply Wall St. âĸ 2026-05-15T12:25:30Z
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
Zacks âĸ 2026-05-07T13:55:02Z
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
Zacks âĸ 2026-04-20T13:55:02Z
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
Zacks âĸ 2026-04-02T16:00:05Z
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
Zacks âĸ 2026-04-02T13:55:02Z
Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed?
Simply Wall St. âĸ 2025-12-12T08:11:48Z
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage
Simply Wall St. âĸ 2025-12-10T16:05:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $371,642,000 | $121,185,000 | $126,036,000 | $93,418,000 |
| Other Income Expense | $-330,207,000 | - | - | - |
| Other Non Operating Income Expenses | $4,151,000 | - | - | - |
| Net Non Operating Interest Income Expense | $5,868,000 | $4,271,000 | $8,173,000 | $1,324,000 |
| Operating Expense | $371,642,000 | $121,185,000 | $126,036,000 | $93,418,000 |
| General And Administrative Expense | $50,110,000 | $27,875,000 | $31,721,000 | $28,868,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Net Interest Income | $5,868,000 | $4,271,000 | $8,173,000 | $1,324,000 |
| Interest Income | $5,868,000 | $4,271,000 | $8,173,000 | $1,324,000 |
| Normalized Income | $-361,623,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Net Income From Continuing And Discontinued Operation | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Total Operating Income As Reported | $-371,642,000 | $-121,185,000 | $-126,036,000 | $-93,418,000 |
| Net Income Common Stockholders | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Net Income | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Net Income Including Noncontrolling Interests | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Net Income Continuous Operations | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Pretax Income | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Interest Income Non Operating | $5,868,000 | $4,271,000 | $8,173,000 | $1,324,000 |
| Operating Income | $-371,642,000 | $-121,185,000 | $-126,036,000 | $-93,418,000 |
| Per Share | ||||
| Diluted EPS | $-70.50 | $-34.03 | $-35.00 | $-46.60 |
| Basic EPS | $-70.50 | $-34.03 | $-35.00 | $-46.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-34,397,000 | $-117,657,000 | $-122,544,000 | $-90,893,000 |
| Total Unusual Items | $-334,358,000 | - | - | - |
| Total Unusual Items Excluding Goodwill | $-334,358,000 | - | - | - |
| Reconciled Depreciation | $2,887,000 | $3,528,000 | $3,492,000 | $2,525,000 |
| EBITDA (Bullshit earnings) | $-368,755,000 | $-117,657,000 | $-122,544,000 | $-90,893,000 |
| EBIT | $-371,642,000 | $-121,185,000 | $-126,036,000 | $-93,418,000 |
| Diluted Average Shares | $9,871,866 | $3,435,533 | $3,359,598 | $1,977,571 |
| Basic Average Shares | $9,871,866 | $3,435,533 | $3,359,598 | $1,977,571 |
| Diluted NI Availto Com Stockholders | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
| Gain On Sale Of Security | $-334,358,000 | - | - | - |
| Research And Development | $321,532,000 | $93,310,000 | $94,315,000 | $64,550,000 |
| Selling General And Administration | $50,110,000 | $27,875,000 | $31,721,000 | $28,868,000 |
| Other Gand A | $50,110,000 | $27,875,000 | $31,721,000 | $28,868,000 |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-164,312,000 | $96,664,000 | $150,724,000 | $250,607,000 |
| Total Assets | $464,126,000 | $142,891,000 | $198,126,000 | $299,366,000 |
| Total Non Current Assets | $6,021,000 | $46,384,000 | $57,323,000 | $62,416,000 |
| Other Non Current Assets | $2,552,000 | $4,796,000 | $7,225,000 | $5,338,000 |
| Current Assets | $458,105,000 | $96,507,000 | $140,803,000 | $236,950,000 |
| Other Current Assets | $1,745,000 | $380,000 | $475,000 | $2,337,000 |
| Prepaid Assets | $1,152,000 | $4,201,000 | $3,153,000 | $4,368,000 |
| Cash Cash Equivalents And Short Term Investments | $455,208,000 | $91,926,000 | $137,175,000 | $230,245,000 |
| Cash And Cash Equivalents | $396,486,000 | $81,949,000 | $31,360,000 | $57,706,000 |
| Debt | ||||
| Total Debt | $3,000,000 | $31,830,000 | $35,660,000 | $38,912,000 |
| Long Term Debt And Capital Lease Obligation | $2,720,000 | $27,615,000 | $31,830,000 | $35,640,000 |
| Current Debt And Capital Lease Obligation | $280,000 | $4,215,000 | $3,830,000 | $3,272,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $628,438,000 | $46,227,000 | $47,402,000 | $48,759,000 |
| Total Non Current Liabilities Net Minority Interest | $603,267,000 | $27,615,000 | $31,830,000 | $35,640,000 |
| Derivative Product Liabilities | $600,547,000 | $0 | - | - |
| Current Liabilities | $25,171,000 | $18,612,000 | $15,572,000 | $13,119,000 |
| Other Current Liabilities | $554,000 | $356,000 | $324,000 | $537,000 |
| Payables And Accrued Expenses | $21,271,000 | $8,189,000 | $5,456,000 | $4,902,000 |
| Payables | $5,127,000 | $1,505,000 | $815,000 | $1,772,000 |
| Accounts Payable | $5,127,000 | $1,505,000 | $815,000 | $1,772,000 |
| Equity | ||||
| Common Stock Equity | $-164,312,000 | $96,664,000 | $150,724,000 | $250,607,000 |
| Total Equity Gross Minority Interest | $-164,312,000 | $96,664,000 | $150,724,000 | $250,607,000 |
| Stockholders Equity | $-164,312,000 | $96,664,000 | $150,724,000 | $250,607,000 |
| Gains Losses Not Affecting Retained Earnings | $41,000 | $22,000 | $-77,000 | $-770,000 |
| Other Equity Adjustments | $41,000 | $22,000 | $-77,000 | $-770,000 |
| Retained Earnings | $-1,152,975,000 | $-456,994,000 | $-340,080,000 | $-222,217,000 |
| Other | ||||
| Ordinary Shares Number | $38,720,196 | $6,238,807 | $3,394,565 | $3,299,806 |
| Share Issued | $38,720,196 | $6,238,807 | $3,394,565 | $3,299,806 |
| Tangible Book Value | $-164,312,000 | $96,664,000 | $150,724,000 | $250,607,000 |
| Invested Capital | $-164,312,000 | $96,664,000 | $150,724,000 | $250,607,000 |
| Working Capital | $432,934,000 | $77,895,000 | $125,231,000 | $223,831,000 |
| Capital Lease Obligations | $3,000,000 | $31,830,000 | $35,660,000 | $38,912,000 |
| Total Capitalization | $-164,312,000 | $96,664,000 | $150,724,000 | $250,607,000 |
| Additional Paid In Capital | $988,604,000 | $553,623,000 | $490,874,000 | $473,587,000 |
| Capital Stock | $18,000 | $13,000 | $7,000 | $7,000 |
| Common Stock | $18,000 | $13,000 | $7,000 | $7,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,720,000 | $27,615,000 | $31,830,000 | $35,640,000 |
| Current Capital Lease Obligation | $280,000 | $4,215,000 | $3,830,000 | $3,272,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,066,000 | $5,852,000 | $5,962,000 | $4,408,000 |
| Current Accrued Expenses | $16,144,000 | $6,684,000 | $4,641,000 | $3,130,000 |
| Net PPE | $3,469,000 | $41,588,000 | $50,098,000 | $57,078,000 |
| Accumulated Depreciation | $-25,000 | $-11,214,000 | $-8,091,000 | $-4,610,000 |
| Gross PPE | $3,494,000 | $52,802,000 | $58,189,000 | $61,688,000 |
| Construction In Progress | $0 | $36,000 | $146,000 | $1,039,000 |
| Other Properties | $2,936,000 | $51,714,000 | $57,012,000 | $59,649,000 |
| Machinery Furniture Equipment | $558,000 | $1,052,000 | $1,031,000 | $1,000,000 |
| Other Short Term Investments | $58,722,000 | $9,977,000 | $105,815,000 | $172,539,000 |
| Treasury Shares Number | - | $0 | - | - |
| Leases | - | - | - | - |
| Properties | - | - | - | - |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-143,654,000 | $-99,889,000 | $-101,361,000 | $-93,606,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-142,713,000 | $-99,660,000 | $-100,292,000 | $-85,144,000 |
| Cash Flow From Continuing Operating Activities | $-142,713,000 | $-99,660,000 | $-100,292,000 | $-85,144,000 |
| Operating Gains Losses | $3,303,000 | $-18,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-941,000 | $-229,000 | $-1,069,000 | $-8,462,000 |
| Investing Cash Flow | $-48,802,000 | $96,857,000 | $71,008,000 | $-94,091,000 |
| Cash Flow From Continuing Investing Activities | $-48,802,000 | $96,857,000 | $71,008,000 | $-94,091,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $328,206,000 | $55,825,000 | $4,578,000 | $115,975,000 |
| Financing Cash Flow | $503,807,000 | $53,392,000 | $2,938,000 | $117,140,000 |
| Cash Flow From Continuing Financing Activities | $503,807,000 | $53,392,000 | $2,938,000 | $117,140,000 |
| Net Other Financing Charges | $-1,325,000 | $-2,325,000 | $-717,000 | - |
| Net Common Stock Issuance | $328,206,000 | $55,825,000 | $4,578,000 | $115,975,000 |
| Common Stock Issuance | $328,206,000 | $55,825,000 | $4,578,000 | $115,975,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $396,654,000 | $84,362,000 | $33,773,000 | $60,119,000 |
| Beginning Cash Position | $84,362,000 | $33,773,000 | $60,119,000 | $122,214,000 |
| Changes In Cash | $312,292,000 | $50,589,000 | $-26,346,000 | $-62,095,000 |
| Proceeds From Stock Option Exercised | $176,926,000 | $-108,000 | $-923,000 | $1,165,000 |
| Net Investment Purchase And Sale | $-48,660,000 | $97,086,000 | $72,077,000 | $-85,629,000 |
| Sale Of Investment | $5,000,000 | $107,000,000 | $147,000,000 | $37,560,000 |
| Purchase Of Investment | $-53,660,000 | $-9,914,000 | $-74,923,000 | $-123,189,000 |
| Net PPE Purchase And Sale | $-142,000 | $-229,000 | $-1,069,000 | $-8,462,000 |
| Sale Of PPE | $799,000 | $0 | - | - |
| Purchase Of PPE | $-941,000 | $-229,000 | $-1,069,000 | $-8,462,000 |
| Change In Working Capital | $10,208,000 | $5,000 | $650,000 | $-9,836,000 |
| Change In Other Current Liabilities | $-2,406,000 | $-3,830,000 | $-3,583,000 | $-10,454,000 |
| Change In Other Current Assets | $0 | $2,429,000 | $-1,887,000 | $-721,000 |
| Change In Payables And Accrued Expense | $10,930,000 | $2,241,000 | $2,850,000 | $1,114,000 |
| Change In Prepaid Assets | $1,684,000 | $-835,000 | $3,270,000 | $225,000 |
| Other Non Cash Items | $518,025,000 | $5,041,000 | $4,727,000 | $3,578,000 |
| Stock Based Compensation | $18,912,000 | $9,847,000 | $13,362,000 | $10,695,000 |
| Amortization Of Securities | $-67,000 | $-1,149,000 | $-4,660,000 | $-12,000 |
| Depreciation Amortization Depletion | $2,887,000 | $3,528,000 | $3,492,000 | $2,525,000 |
| Depreciation And Amortization | $2,887,000 | $3,528,000 | $3,492,000 | $2,525,000 |
| Depreciation | $2,887,000 | $3,528,000 | $3,492,000 | $2,525,000 |
| Gain Loss On Sale Of PPE | $3,303,000 | $-18,000 | $0 | - |
| Net Income From Continuing Operations | $-695,981,000 | $-116,914,000 | $-117,863,000 | $-92,094,000 |
Fetched: 2026-07-17